Clinical Trials and Preclinical Infrastructure Asset Map - Life Sciences

More documents

Recommendations

Info

24 BRITISH COLUMBIA FIGURE 3. Source of Funds for Clinical Trials, 2005/6 - 2009/10 5% 33% Government Industry Not-for-Profit 62% FIGURE 4. Number of Clinical Trials According to Sponsor, 2005/6 - 2009/10 N= 269 (13%) N= 184 (9%) Government Industry Not-for-Profit N= 1596 (78%) Industrial Funders Approximately 260 companies funded clinical trials in B.C. over the past five years. Industrial sponsors included small start-ups and major companies, with investments ranging from less than $1,000 to over $1M. Median sponsorship was $18,700, with 25% of projects receiving more than $53,000. Sponsors included all of the world’s top pharmaceutical and biotech companies. Therapeutic Focus of Clinical Trials Clinical trials in B.C. cover all major disease areas. The most important, based on number of studies over the past five years, are those conducted in cancer, followed by cardiovascular diseases/ cardiology and CNS disorders (Figure 5). In terms of dollars, clinical trials in infectious diseases/ infection received the most funds, in part because of national bulk funding for the CIHR Canadian HIV Trials Network. Cancer, CNS disorders and cardiovascular diseases/ cardiology received the next highest levels of funds (Figure 6).
CLINICAL TRIALS AND PRECLINICAL INFRASTRUCTURE ASSET MAP 25 FIGURE 5. Therapeutic Focus of Clinical Trials Based on a Number of Studies, 2005/6 - 2009/10 7% 14% 23% Cancer CV/Cardiology CNS 4% 4% 4% 18% ID/Infection Gastrointestinal Genitourinary Metabolic/Endocrine 11% 15% Pulmonary Other FIGURE 6. Therapeutic Focus of Clinical Trials Based on Amount of Funding, 2005/06 - 2009/10 6% 6% 9% 23% Cancer CV/Cardiology CNS 3% 3% 9% ID/Infection Gastrointestinal Genitourinary Metabolic/Endocrine 24% 17% Pulmonary Other “Other” includes anesthesiology, autoimmune, critical care, dental, dermatology, emergency medicine, hematology, musculo-skeletal, neonatology, obstetrics and gynecology, ophthalmology, surgery, and transplant. The distribution in terms of disease specialty and funding of the more than 200 pediatric trials included in this report is somewhat different to the overall pattern, as can be seen in Figure 7. Trials on diseases and disorders of the CNS, particularly epilepsy, Fetal Alcohol Spectrum Disorders, and Attention Deficit Hyperactivity Disorder, are the most common, followed by infectious diseases/ infection (mainly vaccine trials) 16 . The most common pulmonary trials targeted cystic fibrosis, respiratory syncytial virus, and asthma. 16 Note that pediatric cancer trials do not come with individual trial funding and funding related to disease underestimates the amount of activity in this area. Using infrastructure funds from the international Children’s Oncology Group (COG), virtually every child is entered into cancer clinical trials that are seamlessly integrated into their health care.
Page 1: M A G N E T I C 12 0 40 33 0 34 0 3
Page 4 and 5: ii BRITISH COLUMBIA
Page 6 and 7: 2 BRITISH COLUMBIA EXECUTIVE SUMMAR
Page 8 and 9: 4 BRITISH COLUMBIA INTRODUCTION Wit
Page 10 and 11: 6 BRITISH COLUMBIA TABLE 1. Health
Page 12 and 13: 8 BRITISH COLUMBIA FIGURE 2. Clinic
Page 14 and 15: 10 BRITISH COLUMBIA TABLE 2. Clinic
Page 26 and 27: 22 BRITISH COLUMBIA Much clinical r
Page 30 and 31: 26 BRITISH COLUMBIA FIGURE 7. Thera
Page 32 and 33: 28 BRITISH COLUMBIA Clinical Invest
Page 34 and 35: 30 BRITISH COLUMBIA TABLE 6. Patien
Page 36 and 37: 32 BRITISH COLUMBIA FIGURE 13. Prov
Page 38 and 39: 34 BRITISH COLUMBIA TABLE 9. Health
Page 40 and 41: 36 BRITISH COLUMBIA TABLE 10. Epide
Page 42 and 43: 38 BRITISH COLUMBIA TABLE 12. Provi
Page 44 and 45: 40 BRITISH COLUMBIA TABLE 13. Examp
Page 46 and 47: 42 BRITISH COLUMBIA TABLE 13. Examp
Page 48 and 49: 44 BRITISH COLUMBIA TABLE 14. Indep
Page 50 and 51: 46 BRITISH COLUMBIA COMPARATIVE POS
Page 52 and 53: 48 BRITISH COLUMBIA ACKNOWLEDGEMENT
Page 54 and 55: 50 BRITISH COLUMBIA APPENDIX 1-2 TA
Page 56 and 57: 52 BRITISH COLUMBIA APPENDIX 1. DES
Page 58 and 59: 54 BRITISH COLUMBIA Edward Miller C
Page 60 and 61: 56 BRITISH COLUMBIA Radiation Thera
Page 62 and 63: 58 BRITISH COLUMBIA The Unit has 15
Page 64 and 65: 60 BRITISH COLUMBIA Neonatal Resear
Page 66 and 67: 62 BRITISH COLUMBIA The B.C. Childr
Page 68 and 69: 64 BRITISH COLUMBIA The clinical tr
Page 70 and 71: 66 BRITISH COLUMBIA FRASER HEALTH A
Page 72 and 73: 68 BRITISH COLUMBIA tional therapis
Page 74 and 75: 70 BRITISH COLUMBIA PROVIDENCE HEAL
Page 76 and 77: 72 BRITISH COLUMBIA Quality control
Page 78 and 79:
74 BRITISH COLUMBIA Clinical trials
Page 80 and 81:
76 BRITISH COLUMBIA The facility ha
Page 82 and 83:
78 BRITISH COLUMBIA Staffing of the
Page 84 and 85:
80 BRITISH COLUMBIA Investigators:
Page 86 and 87:
82 BRITISH COLUMBIA Quality control
Page 88 and 89:
84 BRITISH COLUMBIA The Research Gr
Page 90 and 91:
86 BRITISH COLUMBIA Multiple Sclero
Page 92 and 93:
88 BRITISH COLUMBIA Gastroenterolog
Page 94 and 95:
90 BRITISH COLUMBIA Since the Centr
Page 96 and 97:
92 BRITISH COLUMBIA TABLE A1. Provi
Page 98 and 99:
94 BRITISH COLUMBIA FIGURE A9. Cent
Page 100 and 101:
96 BRITISH COLUMBIA The Unit suppor
Page 102 and 103:
98 BRITISH COLUMBIA TABLE A2. CFRI
Page 104 and 105:
100 BRITISH COLUMBIA Quality contro
Page 106 and 107:
102 BRITISH COLUMBIA • Knowledge
Page 108 and 109:
104 BRITISH COLUMBIA Its staffing i
Page 110 and 111:
106 BRITISH COLUMBIA APPENDIX 3. QU
Page 112 and 113:
108 BRITISH COLUMBIA APPENDIX 5. CL
Page 114 and 115:
110 BRITISH COLUMBIA APPENDIX 5. Cl
Page 116 and 117:
112 BRITISH COLUMBIA APPENDIX 6 TAB
Page 118 and 119:
114 BRITISH COLUMBIA 6.1 Clinical T
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
238 BRITISH COLUMBIA Pediatrics INV
Page 244 and 245:
240 BRITISH COLUMBIA Pediatrics (co
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
248 BRITISH COLUMBIA APPENDICES 7-1
Page 254 and 255:
250 BRITISH COLUMBIA TABLE A3. Pati
Page 256 and 257:
252 BRITISH COLUMBIA TABLE A3. Pati
Page 258 and 259:
254 BRITISH COLUMBIA APPENDIX 8. PR
Page 260 and 261:
256 BRITISH COLUMBIA APPENDIX 8. Pr
Page 262 and 263:
258 BRITISH COLUMBIA APPENDIX 9. He
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
Page 282 and 283:
Page 284 and 285:
Page 286 and 287:
Page 288 and 289:
284 BRITISH COLUMBIA APPENDIX 10. N
Page 290 and 291:
286 BRITISH COLUMBIA Networks In Wh
Page 292 and 293:
Page 294 and 295:
Page 296 and 297:
292 BRITISH COLUMBIA APPENDIX 11. I
Page 298 and 299:
Page 300 and 301:
Page 302 and 303:
Page 304 and 305:
Page 306 and 307:
Page 308 and 309:
Page 310 and 311:
306 BRITISH COLUMBIA APPENDIX 12. P
Page 312 and 313:
Page 314 and 315:
Page 316 and 317:
312 BRITISH COLUMBIA B.C. Centre fo
Page 318 and 319:
314 BRITISH COLUMBIA University of
Page 320:
316 BRITISH COLUMBIA
show all

Clinical Trials and Preclinical Infrastructure Asset Map - Life Sciences

Create successful ePaper yourself

Delete template?

Save as template?